Cymbalta online. Best prices from the TOP pharmacies.

Eli Lilly and Company (NYSE: LLY)
announced today that the U.S. Food and Drug Administration (FDA) has
approved the antidepressant Cymbalta (duloxetine HCl) for the treatment
of generalized anxiety disorder (GAD), a condition that affects more than
6.5 million American adults in a given year(1). Because GAD presents with a
variety of symptoms, it can be difficu…

THE FDA called on Eli Lilly to stop journal ads for Cymbalta as a treatment for nerve pain caused by diabetes because the ads fail to address drug risks.
In a Sept. 9 untitled letter posted by the agency last month, the Divi…

MAKERS OF antidepressants braced themselves as Eli Lilly won approval for Cymbalta (duloxetine), which will be positioned as the first drug to treat the physical as well as the emotional symptoms of depression.
“The most important goal in treating depression is to help the patient reach remission,” said a Lilly spokeswoman, noting that jus…

Data suggest that patients with
generalized anxiety disorder (GAD) treated with Cymbalta (duloxetine
HCl) experienced improved ability to perform everyday activities at home,
work and in social situations compared to sugar pill. These improvements in
glo…

Elderly patients with depression treated with Lilly’s Cymbalta[R] (duloxetine hydro-chloride), 60 mg once daily, had twice as much improvement in verbal learning and recalling information than those given a sugar pill, according to research presented at the annual meeting of the American Association for Geriatric Psychiatry….

Eli Lilly and Company (NYSE: LLY) has
submitted a supplemental New Drug Application (sNDA) to the U.S. Food and
Drug Administration (FDA) seeking approval for a new indication for
Cymbalta (duloxetine HCl) for the management of chronic pain, the
company announced today. The submission is based on outcomes of clinical
trials in chronic osteoarthritis pain of the knee and chronic low back
pain, in addition to data from previously completed pain studies in
diabetic peripheral neuropathi…

Business Editors/Health/Medical Writers
INDIANAPOLIS–(BUSINESS WIRE)–Oct. 1, 2003
No Additional Studies Required before Approval; Final Approval
Contingent upon Resolution of Manufacturing Issues and Completion of
Label Negotiations
The U.S. Food and Drug Administration issued a second approvable letter for Cymbalta(TM) (duloxetine HCl; pronounced SIM-BALL-TA), a potent serotonin and norepinephrine reuptake inhibitor, Eli Lilly and Company (NY…

Eli Lilly said Monday that its antidepressant Cymbalta (duloxetine) has been approved by the U.S. Food and Drug Administration to treat fibromyalgia, a chronic disorder with symptoms including widespread muscle pain and tenderness.
The condition affects about 2 percent of the American population, or about 5 million people, mostly women. While its cause is unknown and there is no known cure, it’s believed it may be related to a combination of changes in brain…

Related Results

Lilly prepares for Cymbalta launch

Duloxetine lifts arthritis pain, aids cognition.(Psychosomatic Medicine)

…

Cymbalta Reduces Pain and Improves Functioning in Fibromyalgia Patients
INDIANAPOLIS, June 16 /PRNewswire-FirstCall/ — The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company announce…